CC
RARE icon

Clearline Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Clearline Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-32,961
Closed -$1.35M – 163
2024
Q2 		$1.35M Buy
+32,961
New +$1.41M 0.04% 109

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Clearline Capital's RARE Position: Q3 2024 in Review

Clearline Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2024, closing a stake of 32,961 shares — an estimated $1.35M sold.

Clearline Capital first reported a position in RARE in Q2 2024 and held it in 1 quarter. The position peaked at $1.35M in Q2 2024. 300 funds tracked by Wall St. Rank hold RARE as of Q3 2024.

  • Clearline Capital reported no remaining Ultragenyx Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • Clearline Capital sold 32,961 Ultragenyx Pharmaceutical shares in Q3 2024, an estimated $1.35M.
  • Clearline Capital first reported a position in Ultragenyx Pharmaceutical in Q2 2024 and held it in 1 quarter.
  • Clearline Capital's Ultragenyx Pharmaceutical position peaked at $1.35M in Q2 2024.
  • 300 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2024.

Based on Clearline Capital's 13F filing for Q3 2024, filed 14 Nov 2024.